Loading clinical trials...
Loading clinical trials...
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Conditions
Interventions
DTRM-555
Locations
8
United States
Mayo Clinic
Phoenix, Arizona, United States
Yale - Smillow Cancer Hospital
New Haven, Connecticut, United States
Mayo Clinic
Jacksonville, Florida, United States
Mayo Clinic
Rochester, Minnesota, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Duke Cancer Institute
Durham, North Carolina, United States
Start Date
April 24, 2020
Primary Completion Date
December 31, 2024
Completion Date
December 31, 2024
Last Updated
January 8, 2025
NCT07260812
NCT05006716
NCT06026319
NCT04195633
NCT04169737
NCT07368270
Lead Sponsor
Zhejiang DTRM Biopharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions